The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.
Q3 2025 Management View CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback